189 related articles for article (PubMed ID: 30944862)
41. Reversal of Latency as Part of a Cure for HIV-1.
Rasmussen TA; Tolstrup M; Søgaard OS
Trends Microbiol; 2016 Feb; 24(2):90-97. PubMed ID: 26690612
[TBL] [Abstract][Full Text] [Related]
42. The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function.
Clutton G; Xu Y; Baldoni PL; Mollan KR; Kirchherr J; Newhard W; Cox K; Kuruc JD; Kashuba A; Barnard R; Archin N; Gay CL; Hudgens MG; Margolis DM; Goonetilleke N
Sci Rep; 2016 Aug; 6():30749. PubMed ID: 27480951
[TBL] [Abstract][Full Text] [Related]
43. A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells.
Offersen R; Nissen SK; Rasmussen TA; Østergaard L; Denton PW; Søgaard OS; Tolstrup M
J Virol; 2016 May; 90(9):4441-4453. PubMed ID: 26889036
[TBL] [Abstract][Full Text] [Related]
44. Distinct chromatin functional states correlate with HIV latency reactivation in infected primary CD4
Battivelli E; Dahabieh MS; Abdel-Mohsen M; Svensson JP; Tojal Da Silva I; Cohn LB; Gramatica A; Deeks S; Greene WC; Pillai SK; Verdin E
Elife; 2018 May; 7():. PubMed ID: 29714165
[TBL] [Abstract][Full Text] [Related]
45. Maraviroc reactivates HIV with potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells.
López-Huertas MR; Jiménez-Tormo L; Madrid-Elena N; Gutiérrez C; Vivancos MJ; Luna L; Moreno S
Biochem Pharmacol; 2020 Dec; 182():114231. PubMed ID: 32979351
[TBL] [Abstract][Full Text] [Related]
46. Low Inducibility of Latent Human Immunodeficiency Virus Type 1 Proviruses as a Major Barrier to Cure.
Siliciano JD; Siliciano RF
J Infect Dis; 2021 Feb; 223(12 Suppl 2):13-21. PubMed ID: 33586775
[TBL] [Abstract][Full Text] [Related]
47. G-quadruplex ligands targeting telomeres do not inhibit HIV promoter activity and cooperate with latency reversing agents in killing latently infected cells.
Piekna-Przybylska D; Bambara RA; Maggirwar SB; Dewhurst S
Cell Cycle; 2020 Sep; 19(18):2298-2313. PubMed ID: 32807015
[TBL] [Abstract][Full Text] [Related]
48. Reactivation capacity by latency-reversing agents ex vivo correlates with the size of the HIV-1 reservoir.
Darcis G; Bouchat S; Kula A; Van Driessche B; Delacourt N; Vanhulle C; Avettand-Fenoel V; De Wit S; Rohr O; Rouzioux C; Van Lint C
AIDS; 2017 Jan; 31(2):181-189. PubMed ID: 27755105
[TBL] [Abstract][Full Text] [Related]
49. SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques.
Dashti A; Waller C; Mavigner M; Schoof N; Bar KJ; Shaw GM; Vanderford TH; Liang S; Lifson JD; Dunham RM; Ferrari G; Tuyishime M; Lam CK; Nordstrom JL; Margolis DM; Silvestri G; Chahroudi A
J Virol; 2020 Oct; 94(21):. PubMed ID: 32817214
[TBL] [Abstract][Full Text] [Related]
50. Establishment of a Novel Humanized Mouse Model To Investigate
Flerin NC; Bardhi A; Zheng JH; Korom M; Folkvord J; Kovacs C; Benko E; Truong R; Mota T; Connick E; Jones RB; Lynch RM; Goldstein H
J Virol; 2019 Mar; 93(6):. PubMed ID: 30626677
[TBL] [Abstract][Full Text] [Related]
51. From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication.
Shan L; Siliciano RF
Bioessays; 2013 Jun; 35(6):544-52. PubMed ID: 23613347
[TBL] [Abstract][Full Text] [Related]
52. Tracking HIV Rebound following Latency Reversal Using Barcoded HIV.
Marsden MD; Zhang TH; Du Y; Dimapasoc M; Soliman MSA; Wu X; Kim JT; Shimizu A; Schrier A; Wender PA; Sun R; Zack JA
Cell Rep Med; 2020 Dec; 1(9):100162. PubMed ID: 33377133
[TBL] [Abstract][Full Text] [Related]
53. The Combination of Venetoclax and Ixazomib Selectively and Efficiently Kills HIV-Infected Cell Lines but Has Unacceptable Toxicity in Primary Cell Models.
Alto A; Natesampillai S; Chandrasekar AP; Krogman A; Misra A; Shweta F; VanLith C; Yao JD; Cummins NW; Badley AD
J Virol; 2021 May; 95(12):. PubMed ID: 33827940
[TBL] [Abstract][Full Text] [Related]
54. Atlas of the HIV-1 Reservoir in Peripheral CD4 T Cells of Individuals on Successful Antiretroviral Therapy.
Gálvez C; Grau-Expósito J; Urrea V; Clotet B; Falcó V; Buzón MJ; Martinez-Picado J
mBio; 2021 Dec; 12(6):e0307821. PubMed ID: 34844430
[TBL] [Abstract][Full Text] [Related]
55. Gnidimacrin, a Potent Anti-HIV Diterpene, Can Eliminate Latent HIV-1 Ex Vivo by Activation of Protein Kinase C β.
Lai W; Huang L; Zhu L; Ferrari G; Chan C; Li W; Lee KH; Chen CH
J Med Chem; 2015 Nov; 58(21):8638-46. PubMed ID: 26509731
[TBL] [Abstract][Full Text] [Related]
56. A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs.
Lassen KG; Hebbeler AM; Bhattacharyya D; Lobritz MA; Greene WC
PLoS One; 2012; 7(1):e30176. PubMed ID: 22291913
[TBL] [Abstract][Full Text] [Related]
57. Therapeutic Approaches to Eradicate Latent HIV-1 in Resting CD4+ T Cells.
Sluis-Cremer N
Curr Top Med Chem; 2016; 16(10):1191-7. PubMed ID: 26324046
[TBL] [Abstract][Full Text] [Related]
58. Thalidomide as a Potential HIV Latency Reversal Agent: Is It the Right Time to Forget the Ancestral Sins?
Vignesh R; Shankar EM
EBioMedicine; 2017 Oct; 24():20-21. PubMed ID: 28865747
[No Abstract] [Full Text] [Related]
59. Nanoparticle-Based Immunoengineered Approaches for Combating HIV.
Bowen A; Sweeney EE; Fernandes R
Front Immunol; 2020; 11():789. PubMed ID: 32425949
[TBL] [Abstract][Full Text] [Related]
60. Heterogeneous HIV-1 Reactivation Patterns of Disulfiram and Combined Disulfiram+Romidepsin Treatments.
Kula A; Delacourt N; Bouchat S; Darcis G; Avettand-Fenoel V; Verdikt R; Corazza F; Necsoi C; Vanhulle C; Bendoumou M; Burny A; De Wit S; Rouzioux C; Rohr O; Van Lint C
J Acquir Immune Defic Syndr; 2019 Apr; 80(5):605-613. PubMed ID: 30768485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]